-
10:48:45 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

EXEL Stock News

06/21/22 8:00 AM
Nasdaq : EXEL
clinical trial
Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer
Exelixis, Inc. today announced the initiation of STELLAR-303, a phase 3 pivotal trial evaluating XL092 in combination with atezolizumab versus regorafenib in patients with metastatic colorectal cancer that is not microsatellite instability-high or mismatch repair-deficient, who have progressed after or are intolerant to the standard of care therapy.
RHEA-AI
neutral
05/26/22 5:00 PM
Nasdaq : EXEL
Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022
Exelixis, Inc. today announced detailed results from multiple cohorts of the phase 1 b COSMIC-021 trial of cabozantinib as a monotherapy and in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. Data from urothelial carcinoma cohorts 3, 4 and 5 and from non-small cell lung cancer cohorts 7 and 20 will be presented...
RHEA-AI
neutral
05/26/22 5:00 PM
Nasdaq : EXEL
clinical trial
Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022
Exelixis, Inc. today announced results from a phase 2, investigator-sponsored trial of cabozantinib in combination with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma. The data will be presented at the 2022 American Society of Clinical Oncology Annual Meeting during Oral Abstract Session: Head and Neck...
RHEA-AI
neutral
05/10/22 4:05 PM
Nasdaq : EXEL
earnings
Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update
Exelixis, Inc. today reported financial results for the first quarter of 2022 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones. “Exelixis had a strong start to 2022 as we continued to gain momentum across all components of our business,” said Michael M. Morrissey,...
RHEA-AI
very positive
05/03/22 8:00 AM
Nasdaq : EXEL
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Exelixis, Inc. today announced that its partner Ipsen received approval from the European Commission for CABOMETYX ® as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma, refractory or not eligible to radioactive iodine who have progressed during or after prior systemic therapy.
RHEA-AI
very positive